Stem Cells & Drug Discovery with Dr. Matthias Steger

Dr. Matthias Steger is co-Founder and CEO of Endogena Therapeutics, a biotech company with a novel drug discovery concept based on selective regulation of endogenous stem cells to repair and regenerate organs and tissues. 

Matthias worked for 22 years in the pharmaceutical-biotech industry. Prior to Endogena, he worked as Global Head of Research & Technology Partnering, at Roche, setting up and managing > 50 collaborations and acquisitions for novel drug modalities, new drug discovery technologies, as well as enabling technologies, such as translational models, biomarkers, and drug delivery/formulation. Matthias has also lead and implemented various corporate strategies exploring novel drug discovery approaches, and as such has initiated and built up Roche’s stem cell research.

In addition, Matthias worked as an independent consultant for various biotech companies, academic institutes and venture capital firms, exploring novel drug discovery – and partnering/investment strategies. He also has prior entrepreneurial experience by building up a pioneering orphan GPCR drug discovery company, which lead to a successful acquisition.  Matthias started his career in research, as a medicinal chemist at Roche, exploring novel platforms and drug design approaches, as well as traditional drug discovery programs. He also gained a financial perspective of the industry as an investment banking analyst at Kepler Equities.

He served as an executive board member of the Alliance for Regenerative Medicine (ARM), as well as the chair of the industry committee of the International Society of Stem Cell Research (ISSCR). Matthias has a Diploma in Organic Chemistry (University of Zürich, Switzerland), and a PhD in Medicinal Chemistry from the University of Sussex, UK, as well as an MBA from HSG (St. Gallen, Switzerland).